Nanomedicine for COVID-19: the role of nanotechnology in the treatment and diagnosis of COVID-19

被引:0
作者
Farzan Vahedifard
Krishnan Chakravarthy
机构
[1] University of California San Diego Health Center,Altman Clinical and Translational Research Institute
[2] University of California San Diego Health Center,Division of Pain Medicine, Department of Anesthesiology
来源
Emergent Materials | 2021年 / 4卷
关键词
Nanomedicine; Nanoparticles; Nanosensors; Severe acute respiratory syndrome coronavirus; Coronavirus 2019; Pandemic;
D O I
暂无
中图分类号
学科分类号
摘要
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the recent outbreak of coronavirus 2019 (COVID-19). Although nearly two decades have passed since the emergence of pandemics such as SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), no effective drug against the CoV family has yet been approved, so there is a need to find newer therapeutic targets. Currently, simultaneous research across the globe is being performed to discover efficient vaccines or drugs, including both conventional therapies used to treat previous similar diseases and emerging therapies like nanomedicine. Nanomedicine has already proven its value through its application drug delivery and nanosensors in other diseases. Nanomedicine and its components can play an important role in various stages of prevention, diagnosis, treatment, vaccination, and research related to COVID-19. Nano-based antimicrobial technology can be integrated into personal equipment for the greater safety of healthcare workers and people. Various nanomaterials such as quantum dots can be used as biosensors to diagnose COVID-19. Nanotechnology offers benefits from the use of nanosystems, such as liposomes, polymeric and lipid nanoparticles, metallic nanoparticles, and micelles, for drug encapsulation, and facilitates the improvement of pharmacological drug properties. Antiviral functions for nanoparticles can target the binding, entry, replication, and budding of COVID-19. The toxicity-related inorganic nanoparticles are one of the limiting factors of its use that should be further investigated and modified. In this review, we are going to discuss nanomedicine options for COVID-19 management, similar applications for related viral diseases, and their gap of knowledge.
引用
收藏
页码:75 / 99
页数:24
相关论文
共 1190 条
[1]  
Lai CC(2020)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges Int. J. Antimicrob. Agents 55 105924-596
[2]  
Shih TP(2020)Social network-based distancing strategies to flatten the COVID-19 curve in a post-lockdown world Nat. Hum. Behav. 4 588-708
[3]  
Ko WC(2020)Coronavirus infections—more than just the common cold JAMA. 323 707-S82
[4]  
Tang HJ(2011)Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009-April 2010) Clin. Infect. Dis. 52 S75-ee44
[5]  
Hsueh PR(2020)Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics Lancet Infect. Dis. 20 e238-1973
[6]  
Block P(2020)Developing Covid-19 vaccines at pandemic speed N. Engl. J. Med. 382 1969-414
[7]  
Hoffman M(2020)The potential role of nanomedicine on COVID-19 therapeutics Ther. Deliv. 11 411-16
[8]  
Raabe IJ(2018)Nano based drug delivery systems: recent developments and future prospects J. Nanobiotechnol. 16 71-2381
[9]  
Dowd JB(2018)Evaluating nanomedicines: obstacles and advancements Methods Mol. Biol. (Clifton, NJ) 1682 3-557
[10]  
Rahal C(2017)Diverse applications of nanomedicine ACS Nano 11 2313-1537